Skip to content

Study · Randomized controlled trial · n = 12 · 2020

11 results

The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.

Juel CTB, Lund A, Andersen MM, Hansen CP, Storkholm JH, Rehfeld JF, van Hall G, Hartmann B, Wewer Albrechtsen NJ, Holst JJ, Vilsbøll T, Knop FK

Diabetologia11 May 2020Cited by 19 (Europe PMC)

PMID32394228 (opens in a new tab)DOI10.1007/s00125-020-05158-9 (opens in a new tab)PepBankPUB-32394228
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In totally pancreatectomised individuals, lixisenatide reduced glucose bsAUC to 548 ± 125 versus 1447 ± 95 mmol/l × min with placebo (p < 0.001).

    In plain wordsIn totally pancreatectomised individuals, lixisenatide reduced post-meal glucose excursions versus placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glucose excursions after pancreatectomy
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg · single doseAs given in this study (human).

    Measurements

    Glucose bsAUC
    548 mmol/l × min
    lixisenatide, pancreatectomy group
    SEM of Glucose bsAUC
    125 mmol/l × min
    lixisenatide, pancreatectomy group
    Glucose bsAUC
    1447 mmol/l × min
    placebo, pancreatectomy group
    SEM of Glucose bsAUC
    95 mmol/l × min
    placebo, pancreatectomy group
    P
    < 0.001
    lixisenatide vs placebo, pancreatectomy group

    Source sentences

    Summary
    Compared with placebo, lixisenatide reduced postprandial plasma glucose excursions in the pancreatectomy group (baseline-subtracted AUC [bsAUC] [mean±SEM]: 548 ± 125 vs 1447 ± 95 mmol/l × min, p < 0.001)
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy controls, glucose bsAUC was -126 ± 12 with lixisenatide versus 222 ± 51 mmol/l × min with placebo (p < 0.001).

    In plain wordsIn healthy individuals, lixisenatide reduced post-meal glucose excursions versus placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glucose excursions in healthy controls
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg · single doseAs given in this study (human).

    Measurements

    Glucose bsAUC
    −126 mmol/l × min
    lixisenatide, control group
    SEM of Glucose bsAUC
    12 mmol/l × min
    lixisenatide, control group
    Glucose bsAUC
    222 mmol/l × min
    placebo, control group
    SEM of Glucose bsAUC
    51 mmol/l × min
    placebo, control group
    P
    < 0.001
    lixisenatide vs placebo, control group

    Source sentences

    Summary
    Compared with placebo, lixisenatide reduced postprandial plasma glucose excursions in the pancreatectomy group (baseline-subtracted AUC [bsAUC] [mean±SEM]: 548 ± 125 vs 1447 ± 95 mmol/l × min, p < 0.001) and in the control group (-126 ± 12 vs 222 ± 51 mmol/l × min, p < 0.001).
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In totally pancreatectomised individuals, peak glucose was 18 ± 1.4 mmol/l with lixisenatide versus 23.3 ± 1.0 mmol/l with placebo (p = 0.008).

    In plain wordsIn totally pancreatectomised individuals, lixisenatide reduced peak glucose versus placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePeak glucose after pancreatectomy
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg · single doseAs given in this study (human).

    Measurements

    Peak glucose concentration
    18 mmol/l
    lixisenatide, pancreatectomy group
    SEM of Peak glucose concentration
    1.4 mmol/l
    lixisenatide, pancreatectomy group
    Peak glucose concentration
    23.3 mmol/l
    placebo, pancreatectomy group
    SEM of Peak glucose concentration
    1 mmol/l
    placebo, pancreatectomy group
    P
    0.008
    lixisenatide vs placebo, pancreatectomy group

    Source sentences

    Summary
    In the pancreatectomy group a mean peak glucose concentration of 23.3 ± 1.0 mmol/l was reached at time point 134 ± 11 min with placebo, compared with a mean peak glucose concentration of 18 ± 1.4 mmol/l (p = 0.008) at time point 148 ± 13 min (p = 0.375) with lixisenatide.
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In totally pancreatectomised individuals, peak glucose occurred at 148 ± 13 min with lixisenatide versus 134 ± 11 min with placebo (p = 0.375).

    In plain wordsIn totally pancreatectomised individuals, peak glucose occurred numerically later with lixisenatide than placebo, without a significant difference.

    Peptide
    Lixisenatide
    Outcome
    IncreaseTime to peak glucose after pancreatectomy
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg · single doseAs given in this study (human).

    Measurements

    Time to peak glucose
    148 min
    lixisenatide, pancreatectomy group
    SEM of Time to peak glucose
    13 min
    lixisenatide, pancreatectomy group
    Time to peak glucose
    134 min
    placebo, pancreatectomy group
    SEM of Time to peak glucose
    11 min
    placebo, pancreatectomy group
    P
    0.375
    lixisenatide vs placebo, pancreatectomy group

    Source sentences

    Summary
    In the pancreatectomy group a mean peak glucose concentration of 23.3 ± 1.0 mmol/l was reached at time point 134 ± 11 min with placebo, compared with a mean peak glucose concentration of 18 ± 1.4 mmol/l (p = 0.008) at time point 148 ± 13 min (p = 0.375) with lixisenatide.
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy controls, peak glucose was 5.5 ± 0.1 mmol/l with lixisenatide versus 8.2 ± 0.4 mmol/l with placebo (p < 0.001).

    In plain wordsIn healthy individuals, lixisenatide reduced peak glucose versus placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePeak glucose in healthy controls
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg · single doseAs given in this study (human).

    Measurements

    Peak glucose concentration
    5.5 mmol/l
    lixisenatide, control group
    SEM of Peak glucose concentration
    0.1 mmol/l
    lixisenatide, control group
    Peak glucose concentration
    8.2 mmol/l
    placebo, control group
    SEM of Peak glucose concentration
    0.4 mmol/l
    placebo, control group
    P
    < 0.001
    lixisenatide vs placebo, control group

    Source sentences

    Summary
    In the control group a mean peak concentration of 8.2 ± 0.4 mmol/l was reached at time point 70 ± 13 min with placebo, compared with a mean peak concentration of 5.5 ± 0.1 mmol/l (p < 0.001) at time point 8 ± 25 min (p = 0.054) with lixisenatide.
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In healthy controls, peak glucose occurred at 8 ± 25 min with lixisenatide versus 70 ± 13 min with placebo (p = 0.054).

    In plain wordsIn healthy individuals, peak glucose occurred numerically earlier with lixisenatide than placebo, without a significant difference.

    Peptide
    Lixisenatide
    Outcome
    DecreaseTime to peak glucose in healthy controls
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg · single doseAs given in this study (human).

    Measurements

    Time to peak glucose
    8 min
    lixisenatide, control group
    SEM of Time to peak glucose
    25 min
    lixisenatide, control group
    Time to peak glucose
    70 min
    placebo, control group
    SEM of Time to peak glucose
    13 min
    placebo, control group
    P
    0.054
    lixisenatide vs placebo, control group

    Source sentences

    Summary
    In the control group a mean peak concentration of 8.2 ± 0.4 mmol/l was reached at time point 70 ± 13 min with placebo, compared with a mean peak concentration of 5.5 ± 0.1 mmol/l (p < 0.001) at time point 8 ± 25 min (p = 0.054) with lixisenatide.
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.
  7. 07HumanRandomized controlled trialMechanism

    In totally pancreatectomised individuals, lixisenatide reduced gastric emptying compared with placebo.

    In plain wordsIn totally pancreatectomised individuals, lixisenatide slowed stomach emptying compared with placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGastric emptying after pancreatectomy
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    20 μg · single doseAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide also reduced gastric emptying and postprandial glucagon responses in the pancreatectomy group (66 ± 84 vs 1190 ± 311 pmol/l × min, p = 0.008) and in the control group (141 ± 100 vs 190 ± 100 pmol/l × min, p = 0.034).
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.
  8. 08HumanRandomized controlled trialMechanism

    In healthy controls, lixisenatide reduced gastric emptying compared with placebo.

    In plain wordsIn healthy individuals, lixisenatide slowed stomach emptying compared with placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreaseGastric emptying in healthy controls
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    20 μg · single doseAs given in this study (human).

    Source sentences

    Summary
    Lixisenatide also reduced gastric emptying and postprandial glucagon responses in the pancreatectomy group (66 ± 84 vs 1190 ± 311 pmol/l × min, p = 0.008) and in the control group (141 ± 100 vs 190 ± 100 pmol/l × min, p = 0.034).
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.
  9. 09HumanRandomized controlled trialMechanism

    In totally pancreatectomised individuals, glucagon responses were 66 ± 84 with lixisenatide versus 1190 ± 311 pmol/l × min with placebo (p = 0.008).

    In plain wordsIn totally pancreatectomised individuals, lixisenatide reduced post-meal glucagon responses versus placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glucagon after pancreatectomy
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    20 μg · single doseAs given in this study (human).

    Measurements

    Postprandial glucagon response
    66 pmol/l × min
    lixisenatide, pancreatectomy group
    SEM of Postprandial glucagon response
    84 pmol/l × min
    lixisenatide, pancreatectomy group
    Postprandial glucagon response
    1190 pmol/l × min
    placebo, pancreatectomy group
    SEM of Postprandial glucagon response
    311 pmol/l × min
    placebo, pancreatectomy group
    P
    0.008
    lixisenatide vs placebo, pancreatectomy group

    Source sentences

    Summary
    Lixisenatide also reduced gastric emptying and postprandial glucagon responses in the pancreatectomy group (66 ± 84 vs 1190 ± 311 pmol/l × min, p = 0.008) and in the control group (141 ± 100 vs 190 ± 100 pmol/l × min, p = 0.034).
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.
  10. 10HumanRandomized controlled trialMechanism

    In healthy controls, glucagon responses were 141 ± 100 with lixisenatide versus 190 ± 100 pmol/l × min with placebo (p = 0.034).

    In plain wordsIn healthy individuals, lixisenatide reduced post-meal glucagon responses versus placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glucagon in healthy controls
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    20 μg · single doseAs given in this study (human).

    Measurements

    Postprandial glucagon response
    141 pmol/l × min
    lixisenatide, control group
    SEM of Postprandial glucagon response
    100 pmol/l × min
    lixisenatide, control group
    Postprandial glucagon response
    190 pmol/l × min
    placebo, control group
    SEM of Postprandial glucagon response
    100 pmol/l × min
    placebo, control group
    P
    0.034
    lixisenatide vs placebo, control group

    Source sentences

    Summary
    Lixisenatide also reduced gastric emptying and postprandial glucagon responses in the pancreatectomy group (66 ± 84 vs 1190 ± 311 pmol/l × min, p = 0.008) and in the control group (141 ± 100 vs 190 ± 100 pmol/l × min, p = 0.034).
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.
  11. 11HumanRandomized controlled trialMechanism

    In healthy controls, C-peptide responses were 18 ± 17 with lixisenatide versus 189 ± 31 nmol/l × min with placebo (p < 0.001).

    In plain wordsIn healthy individuals, lixisenatide reduced post-meal C-peptide responses versus placebo.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial C-peptide in healthy controls
    Study

    n = 12

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    20 μg · single doseAs given in this study (human).

    Measurements

    Postprandial C-peptide response
    18 nmol/l × min
    lixisenatide, control group
    SEM of Postprandial C-peptide response
    17 nmol/l × min
    lixisenatide, control group
    Postprandial C-peptide response
    189 nmol/l × min
    placebo, control group
    SEM of Postprandial C-peptide response
    31 nmol/l × min
    placebo, control group
    P
    < 0.001
    lixisenatide vs placebo, control group

    Source sentences

    Summary
    In the control group, postprandial plasma C-peptide responses were reduced with lixisenatide (18 ± 17 vs 189 ± 31 nmol/l × min, p < 0.001).
    2 context sentences
    Summary · context
    underwent two 3 h liquid mixed-meal tests (with paracetamol for assessment of gastric emptying) after single-dose injection of 20 μg of lixisenatide or placebo.
    Summary · context
    Basal insulin was given the night before each experimental day; no insulin was given during study days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT02640118

The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects

University Hospital, Gentofte, Copenhagenn = 24Aug 2015 to Jul 2016

Diabetes After Total Pancreatectomy

Trial pageClinicalTrials.govUpdated 7 May 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.